公开(公告)号：EP1511473A2

公开(公告)日：2005-03-09

申请号：EP03730117.3

申请日：2003-05-26

申请人： Novartis AG ,  Novartis Pharma GmbH ,  IRM LLC

发明人： FAN, Ying ,  GAO, Wenqi ,  GRAY, Nathanael, S. ,  HINTERDING, Klaus ,  LEFEBVRE, Sophie ,  MI, Yuan ,  NUSSBAUMER, Peter ,  PAN, Shifeng ,  WANG, Wei ,  ZECRI, Frédéric ,  PEREZ, Lawrence, Blas ,  LA MONTAGNE, Kenneth, Richard ,  ETTMAYER, Peter

IPC分类号： A61K31/133 ,  C07C215/28

CPC分类号： C07D263/57 ,  C07C215/28 ,  C07C215/46 ,  C07C217/54 ,  C07C237/30 ,  C07C251/48 ,  C07C255/13 ,  C07C255/43 ,  C07C255/58 ,  C07C311/08 ,  C07C2601/02 ,  C07C2601/08 ,  C07D261/08 ,  C07D317/58 ,  C07D333/20 ,  C07F9/094

摘要： The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them.

公开(公告)号：EP1511473B8

公开(公告)日：2013-07-24

申请号：EP03730117.3

申请日：2003-05-26

申请人： Novartis AG ,  Novartis Pharma GmbH ,  IRM LLC

发明人： FAN, Yi ,  GAO, Wenqi ,  GRAY, Nathanael, S. ,  HINTERDING, Klaus ,  LEFEBVRE, Sophie ,  MI, Yuan ,  NUSSBAUMER, Peter ,  PAN, Shifeng ,  WANG, Wei ,  ZECRI, Frédéric ,  PEREZ, Lawrence, Blas ,  LA MONTAGNE, Kenneth, Richard ,  ETTMAYER, Peter

IPC分类号： C07C215/28 ,  C07C215/46 ,  C07C217/54 ,  C07C237/30 ,  C07C251/48 ,  C07C255/13 ,  C07C255/43 ,  C07C255/58 ,  C07C311/08 ,  C07D261/08 ,  C07D317/58 ,  C07C333/20 ,  C07F9/09 ,  C07D263/57 ,  C07D333/20

CPC分类号： C07D263/57 ,  C07C215/28 ,  C07C215/46 ,  C07C217/54 ,  C07C237/30 ,  C07C251/48 ,  C07C255/13 ,  C07C255/43 ,  C07C255/58 ,  C07C311/08 ,  C07C2601/02 ,  C07C2601/08 ,  C07D261/08 ,  C07D317/58 ,  C07D333/20 ,  C07F9/094

公开(公告)号：EP1511473B1

公开(公告)日：2013-04-17

申请号：EP03730117.3

申请日：2003-05-26

申请人： Novartis AG ,  Novartis Pharma GmbH ,  IRM LLC

发明人： FAN, Ying ,  GAO, Wenqi ,  GRAY, Nathanael, S. ,  HINTERDING, Klaus ,  LEFEBVRE, Sophie ,  MI, Yuan ,  NUSSBAUMER, Peter ,  PAN, Shifeng ,  WANG, Wei ,  ZECRI, Frédéric ,  PEREZ, Lawrence, Blas ,  LA MONTAGNE, Kenneth, Richard ,  ETTMAYER, Peter

IPC分类号： C07C215/28 ,  C07C215/46 ,  C07C217/54 ,  C07C237/30 ,  C07C251/48 ,  C07C255/13 ,  C07C255/43 ,  C07C255/58 ,  C07C311/08 ,  C07D261/08 ,  C07D317/58 ,  C07C333/20 ,  C07F9/09 ,  C07D263/57 ,  C07D333/20

CPC分类号： C07D263/57 ,  C07C215/28 ,  C07C215/46 ,  C07C217/54 ,  C07C237/30 ,  C07C251/48 ,  C07C255/13 ,  C07C255/43 ,  C07C255/58 ,  C07C311/08 ,  C07C2601/02 ,  C07C2601/08 ,  C07D261/08 ,  C07D317/58 ,  C07D333/20 ,  C07F9/094

公开(公告)号：EP2588453A1

公开(公告)日：2013-05-08

申请号：EP11733945.7

申请日：2011-06-28

申请人： IRM LLC ,  Novartis AG

发明人： CHENG, Dai ,  ZHANG, Guobao ,  HAN, Dong ,  GAO, Wenqi ,  PAN, Shifeng ,  SHEN, Lichun ,  LELETI, Rajender Reddy

IPC分类号： C07D213/56 ,  C07D237/08 ,  C07D279/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  A61K31/44 ,  A61P35/00

CPC分类号： C07D417/14 ,  A61K31/50 ,  A61K31/541 ,  A61K45/06 ,  C07D213/56 ,  C07D237/08 ,  C07D279/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12

摘要： The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R
1 , R
2 , R
3 are as defined herein.

公开(公告)号：EP1928236B1

公开(公告)日：2011-11-23

申请号：EP06815653.8

申请日：2006-09-26

申请人： IRM LLC ,  Novartis AG

发明人： MOLTENI, Valentina ,  LI, Xiaolin ,  CHIANELLI, Donatella ,  LOREN, Jon ,  LIU, Yi ,  KARANEWSKY, Donald, S. ,  FURET, Pascal ,  GUAGNANO, Vito ,  YOU, Shuli ,  NABAKKA, Juliet ,  LIU, Xiaodong ,  PAN, Shifeng

IPC分类号： A01N43/42 ,  A61K31/44

CPC分类号： C07D403/04 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/10

摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

公开(公告)号：EP2531498A1

公开(公告)日：2012-12-12

申请号：EP11703560.0

申请日：2011-02-04

申请人： IRM LLC ,  Novartis AG

发明人： TELLEW, John E. ,  PAN, Shifeng ,  WAN, Yongqin ,  XIE, Yongping ,  WANG, Xing ,  WANG, Xia ,  HUANG, Shenlin ,  LIU, Zuosheng ,  ZHANG, Qiong

IPC分类号： C07D401/14 ,  C07D471/04 ,  A61K31/4353 ,  A61P35/00

CPC分类号： C07D471/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07D401/14

摘要： The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R
2 , R
3 , R
4 and R
5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：EP2057146A1

公开(公告)日：2009-05-13

申请号：EP07814982.0

申请日：2007-09-24

申请人： IRM LLC ,  NOVARTIS AG

发明人： ALBAUGH, Pamela ,  CHOPIUK, Gregory S. ,  DING, Qiang ,  HUANG, Shenlin ,  LIU, Zuosheng ,  PAN, Shifeng ,  REN, Pingda ,  WANG, Xia ,  WANG, Xing ,  XIE, Yongping ,  ZHANG, Chengzhi ,  ZHANG, Qiong ,  ZHANG, Guobao ,  POON, Daniel ,  RENHOWE, Paul ,  SENDZIK, Martin

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，ARG，BCR异常活化的疾病或病症 -Abl，BRK，EphB，Fms，Fyn，KDR，c-Kit，LCK，PDGF-R，b-Raf，c-Raf，SAPK2，Src，Tie2和TrkB激酶。

公开(公告)号：EP1928236A2

公开(公告)日：2008-06-11

申请号：EP06815653.8

申请日：2006-09-26

申请人： IRM, LLC ,  Novartis AG

发明人： MOLTENI, Valentina ,  LI, Xiaolin ,  CHIANELLI, Donatella ,  LOREN, Jon ,  LIU, Yi ,  KARANEWSKY, Donald, S. ,  FURET, Pascal ,  GUAGNANO, Vito ,  YOU, Shuli ,  NABAKKA, Juliet ,  LIU, Xiaodong ,  PAN, Shifeng

IPC分类号： A01N43/42 ,  A61K31/44

CPC分类号： C07D403/04 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D409/04 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D491/10

摘要： Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

公开(公告)号：EP1628967B1

公开(公告)日：2014-04-09

申请号：EP04752679.3

申请日：2004-05-19

申请人： IRM LLC

发明人： MI, Yuan ,  PAN, Shifeng ,  GRAY, Nathanael, S. ,  GAO, Wenqi ,  FAN, Yi ,  JIANG, Tao

IPC分类号： C07D413/10 ,  A61K31/4725 ,  C07D333/58 ,  C07D409/06 ,  C07D471/04 ,  C07D473/00 ,  C07D261/20 ,  C07D513/04

CPC分类号： C07D333/58 ,  C07D261/20 ,  C07D409/06 ,  C07D471/04 ,  C07D473/00 ,  C07D513/04

公开(公告)号：EP2170867A1

公开(公告)日：2010-04-07

申请号：EP08770592.7

申请日：2008-06-10

申请人： IRM LLC

发明人： HUANG, Shenlin ,  LIU, Zuosheng ,  ALBAUGH, Pamela, A. ,  WANG, Xing ,  PAN, Shifeng ,  XIE, Yongping ,  ZHANG, Guobao

IPC分类号： C07D401/14 ,  C07D403/04

CPC分类号： C07D401/14 ,  C07D403/04

摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, SAPK2α, Src, SIK, Syk, Tie2 and TrkB kinases.